Trends in lipid management among patients with diabetes

Endocrine Practice

Volumn 12, Issue 4, 2006, Pages 380-387

  Tunceli, Kaan ^a   Pladevall, Manel ^a   Williams, L Keoki ^a,b   Divine, George W ^a   Simpkins, Janine C ^a   Nag, Soma S ^c   Sajjan, Shiva G ^c   Kamal Bahl, Sachin J ^c   Alexander, Charles M ^c   Elston Lafata, Jennifer ^a  

^a HENRY FORD HEALTH SYSTEM   (United States)

^b HENRY FORD HOSPITAL   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NITRATE; SIMVASTATIN; WARFARIN; GLYCOSYLATED HEMOGLOBIN; LIPID; TRIACYLGLYCEROL;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; COMORBIDITY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; PERIPHERAL VASCULAR DISEASE; RETROSPECTIVE STUDY; RISK FACTOR; SMOKING; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; COHORT ANALYSIS; MIDDLE AGED; RISK MANAGEMENT;

ADULT; AGED; AGED, 80 AND OVER; ANTILIPEMIC AGENTS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; COHORT STUDIES; DIABETES COMPLICATIONS; DIABETES MELLITUS; FEMALE; FOLLOW-UP STUDIES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERLIPIDEMIAS; LIPIDS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; RISK MANAGEMENT; TRIGLYCERIDES;

EID: 33750102222     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: 10.4158/EP.12.4.380     Document Type: Article

References (26)

1. Egede LE, Zheng D. Modifiable cardiovascular risk factors in adults with diabetes: prevalence and missed opportunities for physician counseling. Arch Intern Med. 2002;162:427-433.
2. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405-412.
3. LaRosa JC, Hunninghake D, Bush D, et al (Task Force on Cholesterol Issues, American Heart Association). The cholesterol facts: a summary of the evidence relating dietary fats, serum cholesterol, and coronary heart disease; a joint statement by the American Heart Association and the National Heart, Lung, and Blood Institute. Circulation. 1990;81:1721-1733.
4. Rubins HB, Nelson DB, Noorbaloochi S, Nugent S. Effectiveness of lipid-lowering medications in outpatients with coronary heart disease in the Department of Veterans Affairs System. Am J Cardiol. 2003;92:1177-1182.
5. Hafner SM (American Diabetes Association). Dyslipidemia management in adults with diabetes. Diabetes Care. 2004;27(Suppl 1):S68-S71.
6. Grundy SM, Cleeman JI, Merz CN, et al (National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association). Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines [erratum in Circulation. 2004;110:763]. Circulation. 2004;110:227-239.
7. Snow V, Aronson MD, Hornbake ER, Mottur-Pilson C, Weiss KB (Clinical Efficacy Assessment Subcommittee of the American College of Physicians). Lipid control in the management of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2004;140:644-649.
8. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care. 1997;20(Suppl 1):S5-S13.
9. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA. 1993;269:3015-3023.
10. Selby JV. Linking automated databases for research in managed care settings. Ann Intern Med. 1997; 127:719-724.
11. Miller DR, Safford MM, Pogach LM. Who has diabetes? Best estimates of diabetes prevalence in the Department of Veterans Affairs based on computerized patient data. Diabetes Care. 2004;27(Suppl 2):B10-B21.
12. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285: 2486-2497.
13. Shepherd J, Cobbe SM, Ford I, et al (West of Scotland Coronary Prevention Study Group). Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333:1301-1307.
14. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
15. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) full report. Available at: http://www.nhlbi.nih.gov/guidelines/cholesterol. Accessed for verification December 20, 2005.
16. Colhoun HM, Betteridge DJ, Durrington PN, et al (Collaborative Atorvastatin Diabetes Study [CARDS] Investigators). Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364:685-696.
17. Collins R, Armitage J, Parish S, Sleigh P, Peto R (Heart Protection Study Collaborative Group). MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003;361:2005-2016.
18. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA. 2002;288:2998-3007.
19. Sever PS, Dahlof B, Poulter NR, et al (Anglo-Scandinavian Cardiac Outcomes Trial [ASCOT] Investigators). Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361:1149-1158.
20. Vijan S, Hayward RA (American College of Physicians). Pharmacologic lipid-lowering therapy in type 2 diabetes mellitus: background paper for the American College of Physicians. Ann Intern Med. 2004; 140:650-658.
21. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis. 1998;32(5 Suppl 3):S112-S119.
22. Kasiske BL. Hyperlipidemia in patients with chronic renal disease. Am J Kidney Dis. 1998;32(5 Suppl 3):S142-S156.
23. Bogar MD, Basford JR, Thomas RJ. Rate and adequacy of cholesterol screening in patients admitted to a large rehabilitation unit after stroke. Arch Phys Med Rehabil. 2005;86:69-72.
24. Vauthey C, de Freitas GR, van Melle G, Devuyst G, Bogousslavsky J. Better outcome after stroke with higher serum cholesterol levels. Neurology. 2000;54:1944-1949.
25. Collins R, Armitage J, Parish S, Sleight P, Peto R (Heart Protection Study Collaborative Group). Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet. 2004;363:757-767.
26. Heisler M, Smith DM, Hayward RA, Krein SL, Kerr EA. Racial disparities in diabetes care processes, outcomes, and treatment intensity. Med Care. 2003;41:1221-1232.